Conference Proceedings
Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel
Rakesh Awasthi, Karen Thudium Mueller, Gregory A Yanik, Constantine S Tam, Susana Rives, Joseph P McGuirk, Michael A Pulsipher, Michael W Boyer, Ulrich Jaeger, Andre Baruchel, Gary D Myers, Peter Borchmann, Stephen J Schuster, Heather Stefanski, Michael Bishop, Edward R Waldron, Ozlem Anak, Abhijit Chakraborty, Eric Bleickardt, Stephane Wong Show all
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Background: Following infusion of tisagenlecleucel, quantitative polymerase chain reaction (qPCR) can be used to measure in vivo kinetics of CAR transgene. The utility of qPCR to inform individual pt treatment decisions and measure functional persistence is an active area of research. Objective: To determine if CAR transgene detection by qPCR can be used to inform treatment decisions. Methods: Transgene levels in blood measured by qPCR from pivotal phase II studies in pts with relapsed/refractory pediatric and young adult acute lymphoblastic leukemia (pALL; ELIANA [NCT02435849, N=75] and ENSIGN [NCT02228096, N=29]) and adult diffuse large B-cell l..
View full abstract